Results 251 to 260 of about 1,176,323 (360)

AN APPROACH TO THE CHARACTERIZATION OF STEM CELLS IN MOUSE BONE MARROW

open access: green, 1964
Gustavo Cudkowicz   +4 more
openalex   +2 more sources

Suppressing t(4;11) Acute Leukemia by Lipopolymer Nanoparticle Delivery of siRNA Targeting KMT2A::AFF1 with Enhanced Extrahepatic Delivery

open access: yesAdvanced Healthcare Materials, EarlyView.
This study introduces a new lipopolymer nanoparticle (LPNP) system that efficiently delivers siRNA to leukemia cells. The LPNPs silence the leukemia fusion gene KMT2A::AFF1, induce apoptosis, and decrease leukemia burden in mice. These results demonstrate the potential of LPNPs as a targeted siRNA therapy for acute lymphoblastic leukemia.
Mohammad Nasrullah   +9 more
wiley   +1 more source

Advanced Nanoparticle Therapeutics for Targeting Neutrophils in Inflammatory Diseases

open access: yesAdvanced Healthcare Materials, EarlyView.
This review highlights recent advances in nanoparticle‐based strategies to modulate neutrophil activity in inflammatory diseases. By targeting inflammatory neutrophils, NET formation, and neutrophil apoptosis or recruitment, these approaches aim to improve therapeutic precision.
Min Ji Byun   +9 more
wiley   +1 more source

Bioactivity, hemocompatibility, and inflammatory response of calcium incorporated sulfonated polyether ether ketone on mouse-derived bone marrow cells. [PDF]

open access: yesBiosci Rep
Saravanabhavan SS   +6 more
europepmc   +1 more source

Self‐Assembling Multi‐Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma

open access: yesAdvanced Healthcare Materials, EarlyView.
A novel modular T‐cell engager platform, MATCH, is developed for personalized multiple myeloma therapy. MATCH uses complementary oligonucleotide‐linked Fab’ fragments to enable flexible targeting of MM antigens and controlled T‐cell activation. The system shows potent, antigen‐specific cytotoxicity in vitro and in vivo, highlighting its potential for ...
Shannuo Li   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy